Your session is about to expire
← Back to Search
Taxane
Immunotherapy + Chemoradiotherapy for Gastroesophageal Cancer
Phase 1
Waitlist Available
Led By Jaffer A Ajani
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial tests immunotherapy with chemo/radiotherapy to treat unresectable gastroesophageal cancer.
Who is the study for?
This trial is for adults with advanced gastroesophageal cancer that can't be removed by surgery. They should have a good performance status, meaning they're fairly active and able to care for themselves. Participants must not be pregnant or breastfeeding, agree to use contraception, and have adequate organ function as shown by specific blood tests.Check my eligibility
What is being tested?
The study is testing the combination of pembrolizumab (an immune system-boosting drug) with chemoradiotherapy (a mix of chemotherapy drugs and radiation therapy). The goal is to see if this combo is better at controlling gastroesophageal cancer compared to standard treatments.See study design
What are the potential side effects?
Possible side effects include reactions related to the immune system such as inflammation in different parts of the body, infusion-related reactions from the drug entering your bloodstream, fatigue, nausea, low blood counts increasing infection risk, and potential damage to organs from high-energy radiation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical complete response (cCR)
Secondary outcome measures
Median progression free survival (PFS)
Number of participants discontinuing study drug due to AEs
Number of participants experiencing adverse events (AEs)
+4 moreOther outcome measures
Biomarker analysis
Tumor PD-L1 proportion
Tumor T cell infiltrate
+2 moreSide effects data
From 2024 Phase 2 trial • 57 Patients • NCT0300418321%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (pembrolizumab, chemoradiotherapy)Experimental Treatment5 Interventions
See Detailed Description
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oxaliplatin
FDA approved
Radiation Therapy
2017
Completed Phase 3
~7250
Pembrolizumab
FDA approved
Fluorouracil
FDA approved
Docetaxel
FDA approved
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,786 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,651 Total Patients Enrolled
Jaffer A AjaniPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
16 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have an autoimmune disease treated with medication in the last 2 years.I have been treated with specific immune therapy drugs before.I am on replacement therapy like thyroxine or insulin, not systemic treatment.My brain cancer has not worsened recently.I have not had serious heart problems in the last 6 months.My cancer in the stomach or esophagus cannot be removed by surgery.I have fluid buildup in my abdomen or chest but am stable after treatment.I have mild to severe nerve damage in my hands or feet.I am highly allergic to pembrolizumab or its ingredients.My blood clotting tests are normal or within the treatment range if I'm on blood thinners.I have not received any colony-stimulating factors in the last 2 weeks.I have recovered from any major surgery before starting the study.My kidney function tests are within the required range.I agree to use contraception and not donate sperm for 120 days after my last treatment dose.My cancer is advanced and cannot be removed by surgery, or I chose not to have surgery.My brain metastases are stable, and I haven't needed steroids for 14 days.I have had pneumonitis treated with steroids or have it now.I have had treatment for cancer that includes trial medicines.I am currently being treated for an infection.I am fully active or restricted in physically strenuous activity but can do light work.I am not pregnant, not breastfeeding, and meet one of the specified conditions.I may need a blood transfusion due to my tumor causing blood loss.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have a history of hepatitis B or active hepatitis C.I have had radiation therapy for my current illness.I have not received a live vaccine in the last 30 days.My cancer is only in my stomach and not near the area where my stomach meets my esophagus.I haven't had major surgery or significant injury in the last 28 days and don't expect to need major surgery during the study.I have cancer that has spread to my brain or spinal cord.I have received an organ or tissue transplant from another person.I have another cancer that is getting worse or was treated in the last 2 years.I can undergo endoscopic biopsies and give blood for research.I had skin or early cervical cancer but was treated with the intent to cure.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment (pembrolizumab, chemoradiotherapy)
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What medical conditions has Pembrolizumab been approved to treat?
"Pembrolizumab has been found to be effective in treating malignant neoplasms and other health issues such as unresectable melanoma, rectal carcinoma, and microsatellite instability high."
Answered by AI
Has the FDA granted its official authorization for Pembrolizumab?
"Limited data on pembrolizumab's safety and efficacy has caused our team to assign it a rating of 1."
Answered by AI
What is the total sample size of this research experiment?
"Affirmative. Clinicaltrials.gov indicates that the trial, which was first published on September 16th 2020, is currently seeking participants. 15 individuals must be recruited from a single clinical site."
Answered by AI
Are there any vacancies in this trial for participants?
"Via clinicaltrials.gov, we know that this medical study is actively seeking participants. The trial was originally published on September 16th 2020 and recently edited as of October 10th 2022."
Answered by AI
Are there any existing reports of Pembrolizumab being tested in other research projects?
"As of the present day, 1653 separate experiments are exploring Pembrolizumab's capabilities with 375 trials within Phase 3. Guangzhou, Guangdong is a particularly active location in regard to these studies; however, there exists 71618 other sites engaging in research involving Pembrolizumab."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger